An interventional study of Evidence-based standardized Cirrhosis order set in Cirrhosis, Liver, sponsored by University of Alberta. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-21.
Sponsored by University of Alberta · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Liver Cirrhosis with a site in Canada — 7 open to participants now, 11 under way, 2 of them phase 3. Liver Cirrhosis · Canada.
Among the 46 studies in Liver Cirrhosis with a site in Canada, this one has the largest planned enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2019, is one of 13 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 28th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →7 of the 46 studies in Liver Cirrhosis with a site in Canada are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Canada, United States
Ages 18–75
Boehringer Ingelheim · Sites in Canada, United States, Argentina and 34 more countries
Ages 18+
The Cleveland Clinic · Sites in Canada, United States, Brazil and 10 more countries
Ages 18–75 · Healthy volunteers
European Foundation for Study of Chronic Liver Failure · Sites in Canada, United States, Argentina and 24 more countries
Ages 18–80
University Hospital Muenster · Sites in Canada, Belgium, Germany and 1 more country
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,975 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 151 across the 35 interventional studies, 401 across the 10 observational. Of the 31 that completed or were terminated, 11 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 46 have an industry lead sponsor. The 10 most frequent:
University of Alberta is the lead sponsor of 825 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
University of Alberta has 4 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Liver Cirrhosis with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT07885007University Health Network, TorontoAI-SC Multi-center Study | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT07325526Boehringer IngelheimA Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) | 2027-08-05 |
| NCT07927153University Health Network, TorontoProspective AI-SC Trial | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies in Liver Cirrhosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Liver cirrhosis is the leading cause of morbidity and premature mortality in patients with digestive disease. There are many gaps in care which contribute to a high rate of hospital readmissions (44 percent at 90 days) and inadequate quality of care. Currently, there is a lack of structured processes to initiate best practice support for medical and broader health needs of high risk patients.
The cirrhosis care Alberta program (CCAB) is a 3 year multi-component quality improvement initiative which will aim to improve quality of care, reduce acute care utilization and be satisfactory to both patients and providers. Best practice support will be provided in the areas of: Evidence based management of cirrhosis, alcohol use support, frailty, advance care planning, home-hospital-home transitions including standardized outpatient monitoring and structured urgent access for rapid, on-demand outpatient assessment.
Cirrhosis Care Alberta (CCAB) is a 3 year multi-component system-wide quality improvement trial which aims to improve quality of care, reduce acute care utilization and meet the needs of both patients and providers throughout Alberta. Instead of addressing just a single contributor to acute care utilization, this ambitious intervention will be the first in the world to bring together care providers across the province to tackle the complex multilevel problem with a multilevel solution. The intervention includes implementation of our standardized integrated strategy for delivering evidence-based best practices under real-world conditions to address the key determinants of hospital readmission and length of stay (LOS) in patients admitted with cirrhosis.
The CCAB project intervention includes:
Comprehensive Care Bundle (development underway):
Admission and Discharge/Transition order set focused on the screening and management of:
Patient and caregiver education
Provider education
Community Care Pathways
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
o Adult patients who do not have cirrhosis
Current practice at baseline, routine cirrhosis care.
Use of a standardized cirrhosis order set.
Other: Evidence-based standardized Cirrhosis order set
Use of a standardized cirrhosis order set embedded within an electronic medical record.
Other: Evidence-based standardized Cirrhosis order set
Standardized order sets for guidance in ascites, varices, hepatic encephalopathy, infections, and medication reconciliation (optimizing HE medication, medication prophylaxis, withdrawal of non-indicated proton pump inhibitors).
Cumulative hospital length of stay (LOS) per patient year
LOS
Time frame: Baseline, 1 year, 2 year
Hospital Readmission Rate
Readmission rate
Time frame: Baseline,through study completion, an average of 1 year
Mean Length of Stay (LOS) (Ward, ICU, Total)
LOS
Time frame: Baseline,through study completion, an average of 1 year
Readmission rate at 90 days
Readmission rate
Time frame: From commencement of the study (baseline), assessed quarterly until study completion.
Emergency Department (ED) Visit Rate
ED visit rate
Time frame: Baseline,through study completion, an average of 1 year
Outpatient Visit rate
by provider type, location
Time frame: Baseline,through study completion, an average of 1 year
Survival
Patient with cirrhosis survival
Time frame: Baseline,through study completion, an average of 1 year
Disease severity
laboratory values, model for end-stage liver disease (MELD) score
Time frame: Baseline,through study completion, an average of 1 year
Implementation fidelity
Adherence to cirrhosis order set
Time frame: From commencement of the study (baseline), assessed quarterly until study completion.
Plan to share: No
Started Jun 2019 (actual). Primary completion is estimated for Jul 2026, 85 months after the start.
Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 85 months is above that.
Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.